Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2025-02-14 pm EST			5-day change	1st Jan Change
65.94 ^USD	-1.24%		-9.44%	-8.45%

Feb. 06	Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	CI
Feb. 06	Scotiabank Adjusts Bio-Techne's Price Target to $90 From $88	MT

Bio-Techne Corporation Presents at Stephens 26th Annual Investment Conference | NASH2024, Nov-20-2024 11:00 AM

November 20, 2024 at 12:00 pm EST

Presenter Speech
Jacob Johnson (Analysts)

All right. Good morning, everybody. I guess good afternoon to those listening on the East Coast. Welcome to Stephens Conference. I'm Jacob Johnson, life

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Bio-Techne Corporation

Tranche Update on Bio-Techne Corporation's Equity Buyback Plan announced on February 1, 2022.	Feb. 06	CI
Scotiabank Adjusts Bio-Techne's Price Target to $90 From $88	Feb. 06	MT
KeyBanc Adjusts Bio-Techne's Price Target to $90 From $80	Feb. 06	MT
Baird Adjusts Bio-Techne's Price Target to $88 From $86	Feb. 06	MT
RBC Lifts Price Target on Bio-Techne to $80 From $79, Keeps Sector Perform Rating	Feb. 06	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Wednesday	Feb. 05	MT
Bio-Techne Seeks M&A	Feb. 05	CI
Bio-Techne Corporation, Q2 2025 Earnings Call, Feb 05, 2025	Feb. 05
Bio-Techne beats Q2 earnings estimates on improving demand for biotech products	Feb. 05	RE
Bio-Techne's Fiscal Q2 Adjusted Earnings, Net Sales Rise	Feb. 05	MT
Earnings Flash (TECH) Bio-Techne Posts Fiscal Q2 Net Sales $297 Million, vs. FactSet Est of $285.8 Million	Feb. 05	MT
Earnings Flash (TECH) Bio-Techne Posts Fiscal Q2 Adjusted EPS $0.42, vs. FactSet Est of $0.39	Feb. 05	MT
Bio-Techne Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024	Feb. 05	CI
Bio-Techne Appoints Amy E. Herr to Board of Directors	Feb. 04	CI
Baird Adjusts Bio-Techne Price Target to $86 From $84, Maintains Outperform Rating	Jan. 27	MT
Bio-Techne Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	Jan. 14
Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine	Jan. 10	CI
Bio-Techne Prevails in Second Reverse Engineering Claim by Miltenyi Biotec; Shares Up	Jan. 07	MT
Bio-Techne, Waters Strike Co-Marketing, Co-Promotion Deal	Dec. 19	MT
Bio-Techne Signs Distribution Deal With MedSanTek to Expand Product Reach in Turkey	Dec. 12	MT
Medsantek Co. Partners with Bio-Techne Corporation to Bring World-Class Products and Diagnostics in Turkey and Azeri Markets	Dec. 12	CI
Bio-Techne Corporation Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 03:15 PM	Dec. 04
Bio-Techne's Select Fetal Bovine Serum Product Rights, Inventory Acquired by Gemini Bioproducts	Nov. 25	MT
Gemini Bio-Products, Inc. acquired Assets of Bio-Techne Corporation.	Nov. 24	CI
Bio-Techne Corporation Presents at Stephens 26th Annual Investment Conference \| NASH2024, Nov-20-2024 11:00 AM	Nov. 20